Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRK7Q1
|
|||
| Drug Name |
BAY 1238097
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neoplasm [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Bayer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bromodomain and extraterminal domain protein (BET) | Target Info | Inhibitor | [2] |
| KEGG Pathway | SNARE interactions in vesicular transport | |||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02369029) BAY1238097, First in Man. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.